Clinical outcomes of gemtuzumab ozogamicin for relapsed acute myeloid leukemia: single-institution experience
| العنوان: | Clinical outcomes of gemtuzumab ozogamicin for relapsed acute myeloid leukemia: single-institution experience |
|---|---|
| المؤلفون: | Miyuki Ookura, Yasufumi Matsuda, Mihoko Morita, Kazuhiro Itoh, Takahiro Yamauchi, Naoko Hosono, Hiroaki Araie |
| المصدر: | International Journal of Hematology. 113:362-369 |
| بيانات النشر: | Springer Science and Business Media LLC, 2020. |
| سنة النشر: | 2020 |
| مصطلحات موضوعية: | Adult, Male, medicine.medical_specialty, Genes, Wilms Tumor, Gemtuzumab ozogamicin, CD33, Salvage therapy, Hospitals, University, 03 medical and health sciences, Antineoplastic Agents, Immunological, 0302 clinical medicine, Recurrence, Internal medicine, Clinical endpoint, Humans, Medicine, WT1 Proteins, Adverse effect, Aged, Febrile Neutropenia, Retrospective Studies, Aged, 80 and over, Salvage Therapy, Respiratory Distress Syndrome, Hematology, business.industry, Remission Induction, Myeloid leukemia, Middle Aged, medicine.disease, Gemtuzumab, Neoplasm Proteins, Leukemia, Myeloid, Acute, Hematoma, Subdural, Treatment Outcome, 030220 oncology & carcinogenesis, Drug Evaluation, Female, business, Febrile neutropenia, 030215 immunology, medicine.drug |
| الوصف: | We retrospectively evaluated the clinical efficacy and toxicity of gemtuzumab ozogamicin (GO) in patients with relapsed acute myeloid leukemia (AML). Nineteen patients (median 70 years) received GO (9 mg/m2, days 1 and 15) as salvage therapy in our institution between 2006 and 2017. The primary endpoint was the response rate. The secondary endpoint was the occurrence of adverse events. Thirteen patients had de novo AML, and 6 patients had secondary AML. Most of the patients had received salvage treatments more than once prior to GO. Six patients responded to the treatment (31.6%) with 3 complete remissions (15.8%). Five patients had stable disease, and 8 patients did not show any response. GO was more efficacious among the patients with fewer numbers of prior salvage treatments. CD33 positivity of leukemic cells was higher in responders than in nonresponders. Peripheral WT1 mRNA levels mostly decreased over time in the responders. The adverse event most commonly seen was febrile neutropenia (84%). No patient presented with veno-occlusive disease. Three patients died by day 30 (mortality rate 15.8%), one due to acute respiratory distress syndrome and the other two due to sepsis. GO remains an effective salvage treatment. |
| تدمد: | 1865-3774 0925-5710 |
| DOI: | 10.1007/s12185-020-03023-4 |
| URL الوصول: | https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5c74ce6143e21bc1657d586e110554fb https://doi.org/10.1007/s12185-020-03023-4 |
| Rights: | CLOSED |
| رقم الانضمام: | edsair.doi.dedup.....5c74ce6143e21bc1657d586e110554fb |
| قاعدة البيانات: | OpenAIRE |
| تدمد: | 18653774 09255710 |
|---|---|
| DOI: | 10.1007/s12185-020-03023-4 |